This case is the first to report that ACTL therapy has achieved “clinical cure” in a patient with acquired EGFR-TKI resistance, indirectly suggesting the underlying mechanism of this therapy in reshaping the tumor immune microenvironment (TME). This evidence concerns the gene EGFR and neoplasm.